Adc Therapeutics (ADCT)

Trade ADCT now with
11/8/2022 7:07:28 AM ADC Therapeutics SA Q3 Net Loss/shr $0.65 Vs. Loss/shr $0.93 Last Year
11/1/2022 7:18:06 AM ADC Therapeutics Appoints Kristen Harrington-Smith As Chief Commercial Officer
9/16/2022 7:24:13 AM ADC Therapeutics, Sobi Announce ZYNLONTA Gets Positive CHMP Opinion In Europe For R/r Diffuse Large B-cell Lymphoma
8/9/2022 7:09:09 AM ADC Therapeutics Q2 Net Loss $64.4 Mln Or $0.84/Shr Vs Net Loss Of $72.6 Mln Or $0.95/Shr Last Year
7/27/2022 7:43:17 AM ADC Doses First Patient In Phase 1b Trial Of ADCT-601 Targeting AXL
7/20/2022 7:19:06 AM ADC : First Patient Dosed In Phase 2 Trial Of ZYNLONTA Combination In First-Line Diffuse Large B-Cell Lymphoma
7/11/2022 7:23:38 AM Overland ADCT BioPharma Doses First Patient In China With ZYNLONTA With Rituximab In Global Phase 3 Clinical Trial
7/8/2022 3:02:39 AM Sobi To License Loncastuximab Tesirine From ADC Therapeutics
7/8/2022 2:08:43 AM ADC Therapeutics Announces License Deal With Sobi To Develop ZYNLONTA In Europe And Select International Territories
7/1/2022 7:35:12 AM ADC Therapeutics Appoints Jean-Pierre Bizzari To Board
6/29/2022 7:47:49 AM ADC Therapeutics Doses First Patient In Phase 1b Trial Of ZYNLONTA In Combination With Other Anti-cancer Agents
6/13/2022 7:22:10 AM ADC Therapeutics Appoints David Gilman As Chief Business & Strategy Officer
6/10/2022 3:31:35 AM ADC Therapeutics Reports Results From Pivotal Phase 2 Clinical Trial Of Cami In Relapsed Or Refractory Hodgkin Lymphoma
5/9/2022 7:11:37 AM ADC Therapeutics Q1 Net Loss $16.7 Mln Or $0.22/Shr Vs Loss Of $51.5 Mln Or $0.67/Shr Last Year
5/9/2022 7:10:58 AM ADC Therapeutics' Chris Martin Steps Down As CEO
4/4/2022 7:22:00 AM ADC Therapeutics Gets Permanent J-Code For ZYNLONTA From U.S. Centers For Medicare & Medicaid Services
3/3/2022 7:09:44 AM ADC Therapeutics SA Q4 Net Loss $34.4 Mln Vs Net Loss $230 Mln Last Year
1/18/2022 5:13:38 AM ADC Therapeutics Unveils Exclusive License With Mitsubishi Tanabe Pharma To Develop ZYNLONTA In Japan